The molecular underpinnings of these characteristics have been postulated to be secondary to the loss of E-cadherin function, as well as activating mutations in HER2, PI3K, and P53 within the setting of tumor evolution and metastasis [16,34,40]. The gene discussed is CDH1; the disease is neoplasm.